Literature DB >> 12472879

Mitochondrial dysfunction in schizophrenia: a possible linkage to dopamine.

Dorit Ben-Shachar1.   

Abstract

Mitochondria are not only the principal source of high energy intermediates, but play an important role in intracellular calcium buffering, are main producers of reactive oxygen species, and are the source of pro- and antiapoptotic key factors. Moreover, the mitochondria are of a ubiquitous nature and the respiratory chain has a dual genetic basis, i.e. the mitochondrial and the nuclear DNAs. Thus mitochondrial impairment could provide an explanation for the tremendous heterogeneity of clinical and pathological manifestations in schizophrenia. This article reviews several independent lines of evidence that suggest an involvement of mitochondrial dysfunction in schizophrenia. Among them are altered cerebral energy metabolism, mitochondrial hypoplasia, dysfunction of the oxidative phosphorylation system and altered mitochondrial related gene expression. In addition, the interaction between dopamine, a predominant etiological factor in schizophrenia, and mitochondrial respiration is considered as a possible mechanism underlying the hyper- and hypo-activity cycling in schizophrenia. Understanding the role of mitochondria in schizophrenia may encourage novel treatment approaches, the identification of candidate genes and new insights into the pathophysiology and etiology of the disorder.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12472879     DOI: 10.1046/j.1471-4159.2002.01263.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  61 in total

1.  An intercalation mechanism as a mode of action exerted by psychotropic drugs: results of altered phospholipid substrate availabilities in membranes?

Authors:  Ramadhan Oruch; Anders Lund; Ian F Pryme; Holm Holmsen
Journal:  J Chem Biol       Date:  2010-01-27

2.  Mitochondrial-related gene expression changes are sensitive to agonal-pH state: implications for brain disorders.

Authors:  M P Vawter; H Tomita; F Meng; B Bolstad; J Li; S Evans; P Choudary; M Atz; L Shao; C Neal; D M Walsh; M Burmeister; T Speed; R Myers; E G Jones; S J Watson; H Akil; W E Bunney
Journal:  Mol Psychiatry       Date:  2006-04-25       Impact factor: 15.992

Review 3.  Molecular profiling of antipsychotic drug function: convergent mechanisms in the pathology and treatment of psychiatric disorders.

Authors:  Elizabeth A Thomas
Journal:  Mol Neurobiol       Date:  2006-10       Impact factor: 5.590

Review 4.  Oxidative stress in schizophrenia: an integrated approach.

Authors:  Byron K Y Bitanihirwe; Tsung-Ung W Woo
Journal:  Neurosci Biobehav Rev       Date:  2010-10-23       Impact factor: 8.989

Review 5.  Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.

Authors:  Jeffrey A Lieberman; Frank P Bymaster; Herbert Y Meltzer; Ariel Y Deutch; Gary E Duncan; Christine E Marx; June R Aprille; Donard S Dwyer; Xin-Min Li; Sahebarao P Mahadik; Ronald S Duman; Joseph H Porter; Josephine S Modica-Napolitano; Samuel S Newton; John G Csernansky
Journal:  Pharmacol Rev       Date:  2008-09       Impact factor: 25.468

6.  NDUFV2 pseudogene (NDUFV2P1) contributes to mitochondrial complex I deficits in schizophrenia.

Authors:  Oded Bergman; Rachel Karry; Jumana Milhem; Dorit Ben-Shachar
Journal:  Mol Psychiatry       Date:  2018-12-10       Impact factor: 15.992

7.  Kinase network dysregulation in a human induced pluripotent stem cell model of DISC1 schizophrenia.

Authors:  Eduard Bentea; Erica A K Depasquale; Sinead M O'Donovan; Courtney R Sullivan; Micah Simmons; James H Meador-Woodruff; Ying Zhou; Chongchong Xu; Bing Bai; Junmin Peng; Hongjun Song; Guo-Li Ming; Jarek Meller; Zhexing Wen; Robert E McCullumsmith
Journal:  Mol Omics       Date:  2019-06-10

Review 8.  Defects in Bioenergetic Coupling in Schizophrenia.

Authors:  Courtney R Sullivan; Sinead M O'Donovan; Robert E McCullumsmith; Amy Ramsey
Journal:  Biol Psychiatry       Date:  2017-10-24       Impact factor: 13.382

Review 9.  Basal ganglia pathology in schizophrenia: dopamine connections and anomalies.

Authors:  Emma Perez-Costas; Miguel Melendez-Ferro; Rosalinda C Roberts
Journal:  J Neurochem       Date:  2010-01-20       Impact factor: 5.372

10.  The interplay between mitochondrial complex I, dopamine and Sp1 in schizophrenia.

Authors:  Dorit Ben-Shachar
Journal:  J Neural Transm (Vienna)       Date:  2009-11       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.